List view / Grid view
As the global COVID-19 response continues, so does the rapidly expanding pipeline for a novel COVID-19 vaccine. Here, experts from Avalere Health outline ongoing US and global vaccine development efforts, including the role of public-private partnerships in accelerating vaccine development. They will also focus on the broader context of respiratory…
Earlier this year, Johnson & Johnson announced the first major regulatory approval of a vaccine developed by Janssen for the prevention of Ebola. Nikki Withers spoke with the Global Head of Vaccines, Johan Van Hoof, to discover what technologies were used and how they are now being leveraged to develop…
Medical researchers point to a promising route for designing an effective vaccine for the respiratory syncytial virus...
12 January 2017 | By Niamh Marriott, Digital Editor
Topline results from this Phase IIb study to treat children with RSV with inhaled ALX-0171 are expected in the second half of 2018...
21 June 2016 | By Victoria White, Digital Content Producer
A study from University Hospital of Saint-Étienne in France reveals that mobile devices are often also contaminated by viral RNA...
4 May 2016 | By Victoria White, Digital Content Producer
The study met its primary endpoint, demonstrating the favourable safety and tolerability profile of ALX-0171 when administered daily by inhalation...
3 March 2016 | By Emmanuel Hanon, Senior Vice President, Head of Vaccines Research & Development, GSK
Here, GSK's Emmanuel Hanon discusses maternal vaccination and how it has emerged as a promising public health strategy...
13 January 2016 | By Victoria White
The RSV treatment market will rise from approximately $640 million in 2014 to over $2.3 billion by 2024, says research and consulting firm GlobalData...
19 November 2015 | By Victoria White
In the study, treatment with ALS-00876 resulted in a significant reduction of viral load and faster viral clearance versus placebo...
